Severity: Warning
Message: file_get_contents(https://...@gmail.com&api_key=61f08fa0b96a73de8c900d749fcb997acc09&a=1): Failed to open stream: HTTP request failed! HTTP/1.1 429 Too Many Requests
Filename: helpers/my_audit_helper.php
Line Number: 197
Backtrace:
File: /var/www/html/application/helpers/my_audit_helper.php
Line: 197
Function: file_get_contents
File: /var/www/html/application/helpers/my_audit_helper.php
Line: 271
Function: simplexml_load_file_from_url
File: /var/www/html/application/helpers/my_audit_helper.php
Line: 1075
Function: getPubMedXML
File: /var/www/html/application/helpers/my_audit_helper.php
Line: 3195
Function: GetPubMedArticleOutput_2016
File: /var/www/html/application/controllers/Detail.php
Line: 597
Function: pubMedSearch_Global
File: /var/www/html/application/controllers/Detail.php
Line: 511
Function: pubMedGetRelatedKeyword
File: /var/www/html/index.php
Line: 317
Function: require_once
98%
921
2 minutes
20
Three-dimensional printing has the potential to advance current surgical practice, by way of anatomical and pathological structure analysis and customized implant manufacturing. Applications for this technology include pre-operative planning, prosthesis customization, and bioprinting. A comprehensive literature review of PubMed, Embase, Cochrane Library, Scopus, and Web of Science databases was conducted to extract all studies adopting three-dimensional printing in the operative management of primary and metastatic musculoskeletal tumors. A total of 73 articles reporting on 449 patients were deemed eligible for analysis. Indications of three-dimensional printing use consisted mainly of challenging tumor locations and proximity to neighboring neurovascular structures (232 [51.7%] patients) or anticipated high complication rates (142 [31.6%] patients). Operative time and follow-up averaged 240 minutes (4 hours) and 25.8 months, respectively. The majority of patients (327 [72.8%] of 449) in whom three-dimensional printing technology was used did not exhibit any complication or adverse event during or after their surgery, and most (354 [97.3%] of 364) subjects achieved convenient functional and oncological outcomes at last follow-up. The implementation of three-dimensional printing technology in the treatment of bone and soft tissue tumors is safe and efficient, as evidenced by the satisfactory functional and oncological outcomes, as well as the decrease in operative time and complication rates at 2-year follow-up. With recent innovations, three-dimensional printing has become cost-effective and reliable, so it is suitable for applications in orthopedic oncology.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1615/JLongTermEffMedImplants.2021038735 | DOI Listing |